You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


US approval for Sanofi’s late-onset Pompe disease med Nexviazyme

Sanofi’s enzyme replacement therapy (ERT) Nexviazyme (avalglucosidase alfa) has received US Food and Drug Administration (FDA) approval for the treatment of late-onset Pompe disease (LOPD), the French pharma company announced last week.